Latest Interviews
Showing 1–3 of 3 transcripts.
Clear all filters- a16z59 min
Taking Bold Bets: NIH and the Future of Biomedical Science
Dr. Jay Bhattacharya, Erik Torenberg, Vineeta Agarwala, Jorge Conde
Secretary Xavier Becerra announced a $50 million federal investment to launch the Autism Data Science Initiative, selecting 13 teams from 250 applicants to address the rising prevalence of autism and the lack of effective therapies. Concurrently, the NIH is implementing comprehensive reforms to resolve the scientific replication crisis, centralize peer review, and prioritize early-career investigators to foster high-risk innovation. These strategic shifts aim to rebuild public trust through transparent communication, integrate AI for capacity augmentation, and tackle chronic diseases while ensuring rigorous, reproducible medical standards.
- a16z56 min
Faster Science, Better Drugs
Erik Torenberg, Patrick Hsu, Jorge Conde
ARC Institute is establishing a physical hub to integrate machine learning with diverse biological disciplines, aiming to solve complex diseases like Alzheimer's by simulating human cells as digital foundations. Patrick O'Brian leads this effort to transition biological discovery from slow physical experiments to high-speed computation, targeting a "virtual cell" capable of predicting cellular perturbations with 90% accuracy. To validate this progress, the organization has launched the $100,000 Virtual Cell Challenge, seeking to replace traditional trial-and-error methods with AI-driven models that can replicate historic scientific breakthroughs.
- a16z59 min
a16z Podcast | The Science and Business of Innovative Medicines
Jorge Conde, Vijay Pande, Sonal Chokshi, Vas Narasimhan
Novartis transformed its portfolio through a $50 billion restructuring that divested consumer healthcare to prioritize advanced therapies, data science, and proprietary platforms for cell and gene treatments. Under CEO Vas Narasimhan, the company enforces strict "standard of care" mandates for project approval, integrates market access early in development, and invested $15 billion to own specialized infrastructure while leveraging AI for financial forecasting and pathology analysis. This strategic pivot targets a 10% clinical success rate by shifting from bespoke drug development to modular platforms and dedicated digital innovation centers, positioning the firm to address undruggable targets and future modalities like xenotransplantation.